Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 1650 Orleans Street, CRBI, Room 144, Baltimore, MD 21231, USA.
Breast Cancer Res. 2011 Mar 14;13(2):205. doi: 10.1186/bcr2818.
Aromatase inhibitors are widely used as adjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer. While the agents are associated with slightly improved survival outcomes when compared to tamoxifen alone, bone and musculoskeletal side effects are substantial and often lead to discontinuation of therapy. Ideally, the symptoms should be prevented or adequately treated. This review will focus on bone and musculoskeletal side effects of aromatase inhibitors, including osteoporosis, fractures, and arthralgias. Recent advances have been made in identifying potential mechanisms underlying these effects. Adequate management of symptoms may enhance patient adherence to therapy, thereby improving breast cancer-related outcomes.
芳香酶抑制剂被广泛用作激素受体阳性乳腺癌绝经后妇女的辅助治疗。与单独使用他莫昔芬相比，这些药物的生存获益略有改善，但与骨骼和肌肉骨骼相关的副作用显著，且常导致治疗中断。理想情况下，应预防或充分治疗这些症状。本文将重点讨论芳香酶抑制剂的骨骼和肌肉骨骼副作用，包括骨质疏松症、骨折和关节痛。目前已在确定这些作用的潜在机制方面取得了一些进展。充分管理症状可能会提高患者对治疗的依从性，从而改善乳腺癌相关结局。
